Galapagos NV (NASDAQ:GLPG)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research report issued on Wednesday. They presently have a $98.00 price objective on the biotechnology company’s stock. BTIG Research’s target price would suggest a potential upside of 22.03% from the stock’s previous close.
Other analysts have also issued reports about the company. Janney Montgomery Scott upgraded Galapagos NV from a “sell” rating to a “neutral” rating in a research report on Friday, July 7th. They noted that the move was a valuation call. Zacks Investment Research lowered Galapagos NV from a “buy” rating to a “hold” rating in a research report on Monday, April 24th. Cowen and Company reiterated a “buy” rating on shares of Galapagos NV in a research report on Wednesday, June 21st. TheStreet upgraded Galapagos NV from a “d+” rating to a “c” rating in a research report on Wednesday, May 17th. Finally, Instinet reiterated a “buy” rating and issued a $108.00 price objective (down from $121.00) on shares of Galapagos NV in a research report on Thursday, June 22nd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $93.33.
Shares of Galapagos NV (NASDAQ GLPG) traded up 0.068% during midday trading on Wednesday, reaching $80.365. 152,038 shares of the company’s stock were exchanged. Galapagos NV has a 1-year low of $51.91 and a 1-year high of $94.88.
TRADEMARK VIOLATION NOTICE: This news story was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/07/28/galapagos-nv-nasdaqglpg-rating-reiterated-by-btig-research.html.
Hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its stake in shares of Galapagos NV by 18.8% in the first quarter. Bank of America Corp DE now owns 4,379 shares of the biotechnology company’s stock worth $377,000 after buying an additional 694 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Galapagos NV by 45.5% in the second quarter. Bank of Montreal Can now owns 2,828 shares of the biotechnology company’s stock worth $216,000 after buying an additional 884 shares during the period. Aperio Group LLC boosted its position in shares of Galapagos NV by 42.7% in the second quarter. Aperio Group LLC now owns 3,404 shares of the biotechnology company’s stock worth $260,000 after buying an additional 1,018 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Galapagos NV during the first quarter worth about $161,000. Finally, Acadian Asset Management LLC bought a new position in shares of Galapagos NV during the second quarter worth about $166,000. Hedge funds and other institutional investors own 19.94% of the company’s stock.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.
